GLUE Monte Rosa Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1826457 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-61.3%
TTM net income YoY-725.3%
TTM EPS YoY-574.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-214.5%
Net margin-186.2%
FCF margin-248.0%
EBITDA margin-202.8%
Returns
ROE-35.3%
ROA-22.6%
ROIC (approx.)-48.8%
Asset turnover0.12x
Leverage & solvency
Liabilities / assets28.9%
Debt / equity0.00x
Current ratio10.32x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.26x
Accruals ratio6.0%
Payout ratio—
Capex / revenue12.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $54.37M | $8.97M | $4.21M | $2.78M | $12.77M | $23.19M | $84.93M | $60.65M |
| R&D expense | $45.36M | $47.96M | $44.07M | $41.98M | $36.68M | $30.65M | $32.19M | $38.87M |
| SG&A expense | $10.94M | $10.13M | $10.18M | $10.52M | $9.06M | $8.10M | $8.70M | $8.78M |
| Operating income | -$1.94M | -$49.13M | -$50.03M | -$49.72M | -$32.98M | -$15.55M | $44.04M | $13.00M |
| Pretax income | $3.78M | -$43.19M | -$44.45M | -$46.08M | -$30.26M | -$11.10M | $47.71M | $15.60M |
| Income tax | $716,000 | $208,000 | $52,000 | $59,000 | -$3.18M | $1.20M | $822,000 | $2.16M |
| Net income | $3.06M | -$43.40M | -$44.50M | -$46.13M | -$27.08M | -$12.29M | $46.88M | $13.44M |
| EBITDA | $205,000 | -$47.22M | -$48.01M | -$47.63M | -$30.88M | -$13.43M | $46.08M | $15.06M |
| EPS (diluted) | — | — | — | — | — | — | — | — |
| Weighted avg. shares (diluted) | 108.62M | 101.48M | 99.88M | — | 82.40M | 82.19M | 82.96M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $45.18M | $90.10M | $159.86M | $129.88M | $208.34M | $69.43M | $78.53M | $229.12M |
| Current assets | $640.07M | $631.41M | $677.55M | $393.19M | $401.82M | $299.46M | $332.28M | $377.44M |
| PP&E, net | $28.63M | $29.93M | $28.41M | $25.99M | $27.60M | $29.05M | $29.34M | $29.48M |
| Total assets | $697.73M | $691.16M | $736.43M | $448.66M | $459.84M | $359.59M | $393.20M | $438.73M |
| Current liabilities | $62.05M | $59.66M | $71.04M | $64.21M | $61.44M | $41.85M | $59.22M | $156.95M |
| Total liabilities | $201.52M | $203.88M | $214.51M | $215.60M | $214.00M | $91.51M | $118.04M | $215.80M |
| Shareholders' equity | $496.21M | $487.28M | $521.92M | $233.06M | $245.84M | $268.08M | $275.16M | $222.94M |
| Shares outstanding | 85.43M | 85.23M | 84.32M | 65.54M | 61.79M | 61.72M | 61.51M | 61.51M |
| Cash flow statement | ||||||||
| Operating cash flow | -$40.98M | -$44.11M | -$37.37M | -$43.01M | $100.43M | -$34.72M | -$45.49M | $128.92M |
| Capital expenditure | $1.56M | $4.72M | $1.87M | $767,000 | $651,000 | $1.70M | $1.59M | $183,000 |
| Free cash flow | -$42.54M | -$48.84M | -$39.24M | -$43.78M | $99.78M | -$36.41M | -$47.08M | $128.74M |
| Investing cash flow | -$4.54M | -$28.86M | -$261.00M | -$65.07M | $38.14M | $25.32M | -$100.23M | -$30.90M |
| Financing cash flow | $568,000 | $3.21M | $328.33M | $29.62M | $348,000 | $365,000 | $14,000 | $608,000 |
| Depreciation & amortization | $2.14M | $1.91M | $2.03M | $2.09M | $2.10M | $2.12M | $2.05M | $2.06M |
| Stock-based compensation | $6.32M | $5.97M | $5.95M | $4.31M | $4.36M | $4.89M | $5.30M | $4.47M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.